New drug combo tested for tough childhood brain tumors
NCT ID NCT02115074
Summary
This early-stage study aimed to find the safest dose of a two-drug combination (Fluvastatin and Celebrex) for children and young adults whose brain tumors had come back or stopped responding to standard treatments. The trial involved 20 participants across multiple French hospitals. The main goal was to determine the highest dose that could be given without causing severe side effects, to guide future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Angers
Angers, 49933, France
-
Centre Hospitalier de Nancy
Vandœuvre-lès-Nancy, 54511, France
-
Centre Hospitalier de Purpan - Hôpital des Enfants
Toulouse, 31026, France
-
Centre Hospitalier de Strasbourg
Strasbourg, 67098, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Hôpital pour enfants La Timone
Marseille, 13385, France
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.